The World Health Organization (WHO) has published a draft working document outlining key considerations for implementing continuous manufacturing in pharmaceutical production.
Continuous manufacturing, while established in industries like oil refining and food production, remains relatively new in pharmaceuticals. The WHO has emphasized the advantages of this approach, including reduced downtime, improved quality control, and faster production rates.
These changes are seen as particularly important as global health challenges continue to strain pharmaceutical supply chains. The guidelines consider how to transition from traditional batch processing, including technological complexities, workforce training, and regulatory hurdles.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze